Literature DB >> 16395255

Insulin resistance and impaired myocardial fatty acid metabolism in dialysis patients with normal coronary arteries.

M Nishimura1, M Murase, T Hashimoto, H Kobayashi, S Yamazaki, R Imai, K Okino, H Fujita, N Inoue, H Takahashi, T Ono.   

Abstract

We investigated whether insulin resistance is associated with impaired cardiac fatty acid metabolism in maintenance hemodialysis patients without coronary artery disease. We studied 55 nondiabetic (63+/-11 years old) and 51 diabetic (61+/-10 years old) hemodialysis patients with normal coronary arteries, using single-photon emission computed tomography (SPECT) with an iodinated fatty acid analogue, iodine-123-beta-methyl iodophenyl-pentadecanoic acid ((123)I-BMIPP), to evaluate cardiac fatty acid metabolism. SPECT imaging was graded regionally from 0 (normal) to 4 (absence of tracer) to calculate a summed score for 17 left ventricular segments. Insulin resistance was determined using the homeostasis model assessment index of insulin resistance (HOMA-IR). HOMA-IR correlated with summed BMIPP score in nondiabetic and diabetic patients. Stepwise multiple regression analysis showed that HOMA-IR was independently associated with BMIPP summed score in nondiabetic (beta=0.774, t=9.218, P=0.0001) and diabetic patients (beta=0.792, t=9.079, P=0.0001). Left ventricular ejection fraction was lower in nondiabetic subjects with BMIPP summed score of at least 6 plus HOMA-IR of at least 4 than in others with lower values for both assessments (53.1+/-13.8%, n=20 vs 67.7+/-9.1%, n=23, P=0.0002); this was also true in diabetic subjects (50.9+/-15.2%, n=24 vs 71.0+/-13.6%, n=11, P=0.0007). Association between insulin resistance and impaired cardiac fatty acid metabolism may contribute to left ventricular dysfunction in patients with maintenance hemodialysis without coronary diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16395255     DOI: 10.1038/sj.ki.5000100

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

Review 1.  Targeted metabolic imaging to improve the management of heart disease.

Authors:  Moritz Osterholt; Shiraj Sen; Vasken Dilsizian; Heinrich Taegtmeyer
Journal:  JACC Cardiovasc Imaging       Date:  2012-02

Review 2.  The Japanese experience with metabolic imaging in the clinical setting.

Authors:  Nagara Tamaki; Koichi Morita; Yuko Kawai
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

Review 3.  Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.

Authors:  Xiaoliang Wang; Jiang Liu; Christopher A Drummond; Joseph I Shapiro
Journal:  Expert Opin Ther Targets       Date:  2017-04-03       Impact factor: 6.902

Review 4.  Cardiovascular consequences of metabolic syndrome.

Authors:  Johnathan D Tune; Adam G Goodwill; Daniel J Sassoon; Kieren J Mather
Journal:  Transl Res       Date:  2017-01-09       Impact factor: 7.012

5.  Pre-clinical myocardial metabolic alterations in chronic kidney disease.

Authors:  Jeffrey C Fink; Martin A Lodge; Mark F Smith; Anish Hinduja; Jeanine Brown; Mara Y Dinits-Pensy; Vasken Dilsizian
Journal:  Cardiology       Date:  2010-07-07       Impact factor: 1.869

6.  Elevated hepatic 11β-hydroxysteroid dehydrogenase type 1 induces insulin resistance in uremia.

Authors:  Ananda Chapagain; Paul W Caton; Julius Kieswich; Petros Andrikopoulos; Nanda Nayuni; Jamie H Long; Steven M Harwood; Scott P Webster; Martin J Raftery; Christoph Thiemermann; Brian R Walker; Jonathan R Seckl; Roger Corder; Muhammad Magdi Yaqoob
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-25       Impact factor: 11.205

7.  Clinical utility of myocardial fatty acid imaging in patients with end-stage renal disease.

Authors:  Masato Nishimura; Toshihiko Ono
Journal:  J Nucl Cardiol       Date:  2008-09-16       Impact factor: 5.952

8.  Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis.

Authors:  Leszek Niepolski; Alicja E Grzegorzewska; Monika Młot-Michalska
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

9.  Focal impairment in myocardial fatty acid imaging in the left anterior descending artery area, a strong predictor for cardiac death in hemodialysis patients without obstructive coronary artery disease.

Authors:  Masato Nishimura; Tetsuya Hashimoto; Nagara Tamaki; Hiroyuki Kobayashi; Toshihiko Ono
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-27       Impact factor: 9.236

10.  Effects of intravenous l-carnitine on myocardial fatty acid imaging in hemodialysis patients: responders or non-responders to l-carnitine.

Authors:  Masato Nishimura; Toshiko Tokoro; Toru Takatani; Nodoka Sato; Masaya Nishida; Tetsuya Hashimoto; Satoru Yamazaki; Hiroyuki Kobayashi; Toshihiko Ono
Journal:  Springerplus       Date:  2015-07-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.